Werewolf Therapeutics Inc. has announced that it will present new preclinical data at the upcoming Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, scheduled for November 5-9, 2025, in National Harbor, Maryland. The company will showcase three posters highlighting advancements in its conditionally activated therapeutic programs. Presentations will include findings on the sequential administration of WTX-124 and mWTX-330, both INDUKINE™ molecules, demonstrating enhanced antitumor activity in mice without systemic toxicity; the development of conditional T cell engagers (INDUCER™ molecules) designed to reduce dose-limiting cytokine release and off-target toxicity; and pharmacokinetic insights into tumor-specific activation of the IL-2 INDUKINE prodrug WTX-124. The results are scheduled to be presented during the conference and have not yet been disclosed.